Serving the Society Since 1986
Advanced Search
Volume 26 Issue 3
June 2011
    Citation: Jun-jun Shao, Jing-feng Wang, Hui-yun Chang, Ji-xing Liu. Immune Potential of a Novel Multiple-epitope Vaccine to FMDV Type Asia 1 in Guinea Pigs and Sheep .VIROLOGICA SINICA, 2011, 26(3) : 190-197.  http://dx.doi.org/10.1007/s12250-011-3174-0
    shu

    Immune Potential of a Novel Multiple-epitope Vaccine to FMDV Type Asia 1 in Guinea Pigs and Sheep

    • 1.

      College of Veterinary Medicine, Gansu Agricultural University, Lanzhou 730070, China

    • 2.

      State key Laboratory of Veterinary Etiological Biology, Key Laboratory of Animal Virology of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China

    • Corresponding author: Hui-yun Chang, changhuiyun@126.com
      Ji-xing Liu, liujixing@hotmail.com
    • Received Date: 05 November 2011
      Accepted Date: 31 March 2011
      Available online: 01 March 2011

      Fund Project: Key Project of Science and Technology of Gansu Province 092NKDA030National High Technology Research and Development Program of China 2006AA10A204National Science and Technlogy Pillar Program 2006DAD06A03

    • To develop a safe and efficient recombinant subunit vaccine to foot-and-mouth disease virus (FMDV) type Asia 1 in sheep, a tandem repeated multiple-epitope gene consisting of residues 137-160 and 197-211 of the VP1 gene of FMDV was designed and artificially synthesized. The biologically functional molecule, the ovine IgG heavy constant region (oIgG) as a protein carrier was introduced for design of the multiple-epitope recombinant vaccine and recombinant expression plasmids pET-30a-RE and pET-30a-RE-oIgG were successfully constructed. The recombinant proteins, RE and RE-oIgG, were expressed as a formation of inclusion bodies in E. coli. The immune potential of this vaccine regime in guinea pigs and sheep was evaluated. The results showed that IgG could significantly enhance the immune potential of antigenic epitopes. The recombinant protein RE-oIgG could not only elicit the high levels of neutralizing antibodies and lymphocytes proliferation responses in the vaccinated guinea pigs, but confer complete protection in guinea pigs against virus challenge. Although the recombinant protein RE could not confer protection in the vaccinated animals, it could delay the appearance of the clinical signs and reduce the severity of disease. Inspiringly, the titers of anti-FMDV neutralizing antibodies elicited in sheep vaccinated with RE-oIgG was significantly higher than that for the RE vaccination. Therefore, we speculated that this vaccine formulation may be a promising strategy for designing a novel vaccine against FMDV in the future.
    • 加载中

      1. Barteling S J, Vreeswijk J. 1991. Developments in foot-and-mouth disease vaccines. Vaccine, 9 (2): 75-88.
          doi: 10.1016/0264-410X(91)90261-4

      2. Beck E, Strohmaier K. 1987. Subtyping of European foot-and-mouth disease virus strains by nucleotide sequence determination. J Virol, 61: 1621-1629.

      3. Blanco E, Garcia-Briones M, Sanz-Parra A, et al. 2001. Identification of T-cell epitopes in nonstructural proteins of foot-and-mouth disease virus. J Virol, 75 (7): 3164-3174.
          doi: 10.1128/JVI.75.7.3164-3174.2001

      4. Brumeanu T D, Casares S, Dehazya P, et al. 1997. Presentation of a viral peptide assembled on the carbohydrate moieties of immunoglobulin does not require processing. Eur J Immunol, 27 (9): 2408-2416.
          doi: 10.1002/(ISSN)1521-4141

      5. Brumeanu T D, Swiggard W J, Steinman R M, et al. 1993. Efficient loading of identical viral peptide onto class Ⅱ molecules by antigenized immunoglobulin and influenza virus. J Exp Med, 178 (5): 1795-1799.
          doi: 10.1084/jem.178.5.1795

      6. Cedillo-Barrón L, Foster-Cuevas M, Belsham G J, et al. 2001. Induction of a protective response in swine vaccinated with DNA encoding foot-and-mouth disease virus empty capsid proteins and the 3D RNA polymerase. J Gen Virol, 82: 1713-1724.
          doi: 10.1099/0022-1317-82-7-1713

      7. Chan E W C, Wong S C S, Cheng W Y, et al. 2001. An immunoglobulin G based chimeric protein induced foot-and-mouth disease specific immune response in swine. Vaccine, 19: 538-546.

      8. Collen T, Dimmarchi R, Doel T R. 1991, A T cell epitope in VP1 of foot-and-mouth disease virus is immunodominant for vaccinated cattle. J Immunol, 146: 749-755.

      9. Doel T R. 2005. Natural and vaccine induced immunity to FMD. Curr Top Microbiol Immunol, 288: 103-131.

      10. Doel T R. 2003. FMD vaccines. Virus Res, 91: 81-99.
          doi: 10.1016/S0168-1702(02)00261-7

      11. Gerner W, Hammer S E, Wiesmüller K H, et al. 2009. Identification of major histocompatibility complex restriction and anchor residues of foot-and-mouth disease virus-derived bovine T-cell epitopes. J Virol, 83: 4039-4050.
          doi: 10.1128/JVI.01534-08

      12. Golde W T, Pacheco J M, Duque H, et al. 2005. Vaccination against foot-and-mouth disease virus confers complete clinical protection in 7 days and partial protection in 4 days: Use in emergency outbreak response. Vaccine, 23: 5775-5782.
          doi: 10.1016/j.vaccine.2005.07.043

      13. Grubman M J, Baxt B. 2004. Foot and mouth disease. Clin Microbiol Rev, 17 (2): 465-493.
          doi: 10.1128/CMR.17.2.465-493.2004

      14. He C, Wang H, Wei H, et al. 2010. A recombinant truncated FMDV 3AB protein used to better distinguish between infected and vaccinated cattle. Vaccine, 28 (19): 3435-2439.
          doi: 10.1016/j.vaccine.2010.02.072

      15. Kadkhodayan S, Knapp M S, Schmidt J J, et al. 2000. Cloning, Expression, and One-Step Purification of the Minimal Essential Domain of the Light Chain of Botulinum Neurotoxin Type A. Protein Expr Purif, 19: 125-130.
          doi: 10.1006/prep.2000.1227

      16. Mackay D K, Forsyth M A, Davies P R, et al. 1998. Differentiating infection from vaccination in foot-and-mouth disease using a panel of recombinant, nonstructural proteins in ELISA. Vaccine, 16 (5): 446-459.
          doi: 10.1016/S0264-410X(97)00227-2

      17. Rodriguez L L, Barrera J, Kramer E, et al. 2003. A synthetic peptide containing the consensus sequence of the G-H loop region of foot-and-mouth disease virus type O VP1 and a promiscuous T-helper epitope induces eptide-specific antibodies but fails to protect cattle against viral challenge. Vaccine, 21: 3751-3756.
          doi: 10.1016/S0264-410X(03)00364-5

      18. Rodriguez L L, Grubman M. 2009. Foot and mouth disease virus vaccines. Vaccine, 27: D90-D94.
          doi: 10.1016/j.vaccine.2009.08.039

      19. Shao J J, Wong C K, Lin T, et al. 2011. Promising multiple-epitope recombinant vaccine against foot-and-mouth disease virus type O in swine. Clin Vaccine Immunol, 18 (1): 143-149.
          doi: 10.1128/CVI.00236-10

      20. Su C X, Duan X G, Wang X Q, et al. 2007. Heterologous of FMDV immunodominant epitopes and HSP70 in P.pastoris and the subesequent immune response in mice. Vet Mirobiol, 124: 256-263.

      21. Sutmoller P, Barteling S S, Olascoaga R C, et al. 2003. Control and eradication of foot-and-mouth disease. Virus Res, 91 (1): 101-144.
          doi: 10.1016/S0168-1702(02)00262-9

      22. Taboga O, Tami C, Carrillo E, et al. 1997. A largescale evaluation of peptide vaccines against foot-and-mouth disease: lack of solid protection in cattle and isolation of escape mutants. J Virol, 71: 2606-2614.

      23. van Lierop M J, Wagenaar J P, van Noort J M, et al. 1995. Sequences derived from the highly antigenic VP1 region 140 to 160 of foot-and-mouth disease virus do not prime for a bovine T-cell response against intact virus. J Virol, 69: 4511-4514.

      24. Yi J Z, Liu M Q, Zhu C Z, et al. 2004. Recombinant bivalent vaccine against foot-and-mouth disease virus serotype O/A infection in guinea pig. Acta Biochim Biophys Sin (Shanghai), 36 (9): 589-596.
          doi: 10.1093/abbs/36.9.589

      25. Zaghouani H, Steinman R, Nonacs R, et al. 1993. Presentation of a viral T cell epitope expressed in the CDR3 region of a self immunoglobulin molecule. Science, 259: 224-227.
          doi: 10.1126/science.7678469

    • 加载中

    Figures(6) / Tables(1)

    PDF

    Article Metrics

    Article views(3595) PDF downloads(15) Cited by()

    Related
    Proportional views

      Immune Potential of a Novel Multiple-epitope Vaccine to FMDV Type Asia 1 in Guinea Pigs and Sheep

        Corresponding author: Hui-yun Chang, changhuiyun@126.com
        Corresponding author: Ji-xing Liu, liujixing@hotmail.com
      • 1. College of Veterinary Medicine, Gansu Agricultural University, Lanzhou 730070, China
      • 2. State key Laboratory of Veterinary Etiological Biology, Key Laboratory of Animal Virology of Ministry of Agriculture, Lanzhou Veterinary Research Institute, Chinese Academy of Agricultural Sciences, Lanzhou 730046, China
      • Received Date: 05 November 2011
      • Accepted Date: 31 March 2011
      Fund Project:  Key Project of Science and Technology of Gansu Province 092NKDA030National High Technology Research and Development Program of China 2006AA10A204National Science and Technlogy Pillar Program 2006DAD06A03

      Abstract: To develop a safe and efficient recombinant subunit vaccine to foot-and-mouth disease virus (FMDV) type Asia 1 in sheep, a tandem repeated multiple-epitope gene consisting of residues 137-160 and 197-211 of the VP1 gene of FMDV was designed and artificially synthesized. The biologically functional molecule, the ovine IgG heavy constant region (oIgG) as a protein carrier was introduced for design of the multiple-epitope recombinant vaccine and recombinant expression plasmids pET-30a-RE and pET-30a-RE-oIgG were successfully constructed. The recombinant proteins, RE and RE-oIgG, were expressed as a formation of inclusion bodies in E. coli. The immune potential of this vaccine regime in guinea pigs and sheep was evaluated. The results showed that IgG could significantly enhance the immune potential of antigenic epitopes. The recombinant protein RE-oIgG could not only elicit the high levels of neutralizing antibodies and lymphocytes proliferation responses in the vaccinated guinea pigs, but confer complete protection in guinea pigs against virus challenge. Although the recombinant protein RE could not confer protection in the vaccinated animals, it could delay the appearance of the clinical signs and reduce the severity of disease. Inspiringly, the titers of anti-FMDV neutralizing antibodies elicited in sheep vaccinated with RE-oIgG was significantly higher than that for the RE vaccination. Therefore, we speculated that this vaccine formulation may be a promising strategy for designing a novel vaccine against FMDV in the future.

        HTML